EnteroBiotix Limited (‘EnteroBiotix’), a biopharmaceutical company developing best-in-class microbiome therapies for gut health, today announces the completion of a £19m ($25m) financing to advance its lead candidate, EBX-102-02, a next-generation orally delivered full-spectrum investigational microbiome therapeutic, into Phase 2b development for Irritable Bowel Syndrome with Constipation (IBS-C).
For full details please click here.